. 2020 Sep 25;14(1):100873. doi: 10.1016/j.tranon.2020.100873

Table 1.

Tumor-free fraction of mice 154 days following treatment with specific ²¹¹At-farletuzumab; unspecific ²¹¹At-rituximab; unlabeled investigational farletuzumab; or PBS.

	Tumor-free fraction (TFF)
Group A (n = 22); (specific) ²¹¹At-farletuzumab	20 of 22	91%
Group B (n = 22); (unspecific) ²¹¹At-rituximab	3 of 22	14%
Group C (n = 11); unlabeled investigational farletuzumab	1 of 11	9%
Group D (n = 8); PBS	1 of 8	12%